Family Eye Care Center, Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 515 Cash Rd Sw, Camden, AR 71701 Phone: 870-836-2525 Fax: 870-836-7252 |
Charles G Pope Odpa Optometrist Medicare: Medicare Enrolled Practice Location: 130 Eagle Ave, Camden, AR 71701 Phone: 870-836-6886 Fax: 870-836-2345 |
Alyssa L Scott-nutt, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 515 Cash Rd Sw, Camden, AR 71701 Phone: 870-836-2525 Fax: 870-836-7252 |
Charles G Pope, OD Optometrist Medicare: Medicare Enrolled Practice Location: 130 Eagle Ave, Camden, AR 71701 Phone: 870-836-6886 Fax: 870-836-2345 |
Family Eye Care Center Optometrist Medicare: Not Enrolled in Medicare Practice Location: 515 Cash Rd Sw, Camden, AR 71701 Phone: 870-836-2525 Fax: 870-836-7252 |
Dr. Kristen D Teague, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1421 Country Club Rd, Camden, AR 71701 Phone: 870-836-7319 Fax: 870-836-7310 |
Charles Wilson Pope, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 130 Eagle Ave, Camden, AR 71701 Phone: 870-836-6886 Fax: 870-836-2345 |
Mr. Jerry Randall Nutt Jr., O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 515 Cash Rd Sw, Camden, AR 71701 Phone: 870-836-2525 Fax: 870-836-7252 |
Teague Eye Care Center Pa Optometrist Medicare: Medicare Enrolled Practice Location: 1421 Country Club Rd, Camden, AR 71701 Phone: 870-836-7319 Fax: 870-836-7310 |
News Archive
ForeverGreen Worldwide Corp., manufacturer and distributor of all natural whole foods, today announced that it has filed 2010 Q2 financial reports.
Results from a first-of-its-kind study of a multicancer blood test in more than 9,900 women with no evidence or history of cancer showed the liquid biopsy test safely detected 26 undiagnosed cancers, enabling potentially curative treatment.
A new study reveals that preventive medications-such as those to lower blood pressure or cholesterol, or to protect bone health, among others-are commonly prescribed during the last year of life of older adults with cancer, even though they are unlikely to provide meaningful benefits.
Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life. The publication also notes that further economic benefits would have been found had reduced visits to clinics been taken into account.
› Verified 1 days ago